Metabolic & Endocrine · Clinical trials
Acromegaly Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About acromegaly — and why its trials are hard
Acromegaly is a rare, chronic disease caused almost always by a growth-hormone (GH)-secreting pituitary adenoma, driving excess insulin-like growth factor 1 (IGF-1) and progressive somatic overgrowth, cardiovascular, metabolic and respiratory morbidity. Transsphenoidal surgery is first-line, but many patients need medical therapy for residual or recurrent disease. The pharmacologic backbone is the long-acting somatostatin receptor ligands (SRLs) octreotide LAR and lanreotide depot, which normalize GH and IGF-1 in roughly half of patients. Second-generation pasireotide LAR helps some SRL-resistant patients at the cost of hyperglycemia. The GH-receptor antagonist pegvisomant normalizes IGF-1 in the large majority regardless of tumor secretion. In 2020 oral octreotide (Mycapssa) offered the first oral SRL, improving convenience for responders. Biochemical targets are age-normalized IGF-1 and random GH below about 1 ng/mL. Despite effective options, control remains incomplete for a meaningful minority, injections burden patients, and hyperglycemia and gastrointestinal effects persist, sustaining interest in oral and receptor-selective agents.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Octreotide LAR (Sandostatin LAR) | 1998 | First-line medical therapy after inadequate surgery; somatostatin receptor ligand | Sandostatin LAR registration and pooled studies | Normalization of GH and IGF-1 | Biochemical control (GH <2.5 ng/mL and normal IGF-1) in roughly 55-65% of selected patients |
| Lanreotide depot/autogel (Somatuline Depot) | 2007 | First-line/maintenance somatostatin receptor ligand | PRIMARYS | Normalization of GH and IGF-1 | Approximately 54% achieved normal IGF-1 and/or GH <2.5 ng/mL over 48 weeks in treatment-naive patients |
| Pegvisomant (Somavert) | 2003 | GH-receptor antagonist for inadequately controlled disease | Pivotal pegvisomant trial (Trainer et al., NEJM 2000) | Normalization of serum IGF-1 | IGF-1 normalized in about 90% at 12 weeks at the highest dose; long-term registry ~63-73% |
| Pasireotide LAR (Signifor LAR) | 2014 | Second-generation SRL for patients inadequately controlled on first-generation SRLs | C2305 (head-to-head vs octreotide LAR) and C2402 (PAOLA) | Biochemical control (GH <2.5 ng/mL and normal IGF-1) | 31% vs 19% for octreotide LAR at 12 months in C2305; superior control in resistant patients in PAOLA |
| Oral octreotide (Mycapssa) | 2020 | Oral somatostatin analog for responders to injectable SRLs | CHIASMA OPTIMAL | Maintenance of biochemical response (IGF-1 ≤1.0x ULN) at week 36 | 58% maintained response on oral octreotide vs 19% placebo |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in acromegaly development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| ATL1103 (antisense oligonucleotide targeting GH receptor) — Phase II IGF-1-lowering study | Lowered serum IGF-1 but did not advance to a pivotal registration program; development discontinued (unverified specifics) | Injection-site reactions, financing/strategic decisions, and competition from established SRLs and pegvisomant |
Choosing the right endpoint
Primary endpoints that matter in acromegaly trials
- Age-normalized IGF-1 — Primary long-term biochemical marker of disease control and the main regulatory endpoint
- Random/nadir GH — Target typically <1.0 ng/mL (ultrasensitive assays); GH <2.5 ng/mL used in older trials
- Biochemical control composite — Combined GH <2.5 ng/mL plus normal IGF-1 used in SRL registration trials
- Tumor volume reduction — MRI-based secondary endpoint relevant for SRLs with antiproliferative effect
- Symptom/signs and quality of life (AcroQoL) — Patient-reported outcome capturing headache, soft-tissue swelling and function
How iNGENū runs acromegaly trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Acromegaly clinical trials — FAQs
Is surgery or medication first-line for acromegaly?
What does Mycapssa add over injections?
How is treatment success defined?
Ready to discuss your acromegaly trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal